Luminate Medical vs Revvity
Side-by-side comparison of AI visibility scores, market position, and capabilities
Dublin oncology device company developing at-home scalp cooling to prevent chemo hair loss; $22M YC and 8VC-backed with $15M Atlantic Bridge Series A pursuing FDA clearance for at-home oncology care model.
About
Luminate Medical is a Dublin, Ireland-based healthcare technology company developing patient-centered oncology care devices — most notably a next-generation scalp cooling system that prevents or reduces chemotherapy-induced hair loss (alopecia), one of the most psychologically distressing side effects of cancer treatment. Backed by Y Combinator, 8VC, and Atlantic Bridge with $22 million raised total including a $15 million Series A led by Atlantic Bridge in 2024 and a €6.4 million Irish Government grant in 2025, Luminate is pursuing FDA clearance for US market entry with first commercial revenues expected in 2025.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
About
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.